Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center-Reference-Cited by-同舟云学术

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center

Published:2020-05 Issue:5 Volume:40 Page:222-233
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Lu Qianyi¹,Lee Kaping¹,Xu Fei¹,Xia Wen¹,Zheng Qiufan¹,Hong Ruoxi¹,Jiang Kuikui¹,Zhai Qinglian¹,Li Yuan¹,Shi Yanxia¹,Yuan Zhongyu¹,Wang Shusen¹^ORCID

Affiliation:

1. Department of Medical OncologyState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat‐sen University Cancer Center Guangzhou Guangdong 510060 P. R. China

Funder

Joint Fund of National Natural Science Foundation of China

Research Data Deposit

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12029

Reference34 articles.

1. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice;Hanahan D;J Clin Invest,2000

2. The anti-angiogenic basis of metronomic chemotherapy

3. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development

4. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

5. The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bovine serum albumin-coated ZIF-8 nanoparticles to enhance antitumor and antimetastatic activity of methotrexate: in vitro and in vivo study;Journal of Biomaterials Science, Polymer Edition;2024-07-22

2. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer;Breast Cancer Research and Treatment;2023-11-29

3. Facile Fabrication of Dual‐Activatable Gastrointestinal‐Based Nanocarriers for Safe Delivery and Controlled Release of Methotrexate;ChemPlusChem;2023-10-06

4. Low-grade serous ovarian cancer with BRAFV600E mutation treated with metronomic chemotherapy — a case report and literature review;Oncology in Clinical Practice;2023-09-08

5. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer;Medicine;2023-07-14